ADAM CARVER, MD
Ophthalmology Physician · SPRINGFIELD, MO
Individual Active NPI 1588824221
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 1,037 | 17,175 | $7,401,263 | $2,846,233 | $2,215,044 |
| 2023 | 1,010 | 15,002 | $7,441,441 | $3,007,569 | $2,345,769 |
| 2022 | 1,010 | 11,281 | $7,109,416 | $2,914,946 | $2,283,097 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | 6,060 | $35 | $27 |
| 92134 | Imaging of retina | 2,939 | $36 | $27 |
| J0178 | Injection, aflibercept, 1 mg | 2,004 | $827 | $658 |
| 67028 | Injection of drug into eye | 1,977 | $119 | $87 |
| 92014 | Established patient complete exam of visual system | 1,390 | $112 | $79 |
| J9035 | Injection, bevacizumab, 10 mg | 1,007 | $72 | $55 |
| J7999 | Compounded drug, not otherwise classified | 512 | $46 | $36 |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | 222 | $140 | $95 |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 182 | $202 | $161 |
| 92004 | New patient complete exam of visual system | 175 | $134 | $94 |
| 67210 | Destruction of growth of retina using a laser | 164 | $565 | $438 |
| 92012 | Established patient problem focused exam of visual system | 95 | $79 | $59 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Ophthalmology Physician | 207W00000X | ✓ | 2014004822 | MO |
| Ophthalmology Physician | 207W00000X | 26575 | OK |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Ophthalmology Physician providers in Missouri
- NPI 1811493729
- NPI 1275679037
- NPI 1952729600
- NPI 1194721100
- NPI 1104826965
- NPI 1821101189
- NPI 1396888640
- NPI 1093701211
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.